Security key
05338F306
Avalo Therapeutics, Inc. - COMMON STOCK (AVTX)
CUSIP: 05338F306
Q1 2024 13F Holders as of 31 Mar 2024
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 87,507
- Total 13F value
- $1,897,924
- Share change
- +64,537
- SEC-reported price per share
- $21.75
- Number of holders
- 18
- Value change
- +$1,405,693
- Number of buys
- 10
- Number of sells
- 6
- Shares outstanding
- 53,624,847
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2024
Institutions
18
Top holders
10
AVTX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
Avalo Therapeutics, Inc. SEC filings
Avalo Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 05338F306
Recent filing periods:
Ownership snapshot
Top reported holders of AVTX - Avalo Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
0/15
Latest evidence
31 Dec 2023
3/4/5
13F
Highest disclosed value: $397,771
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC has the largest disclosed position value at $397.8K.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Disclosed position value
Top 5
ARMISTICE CAPITAL, LLC
$397.8K
BlackRock Finance, Inc.
$144.5K
NATIXIS
$43.3K
James Archie Harrell Jr.
$19.1K
H. Jeffrey Wilkins
$17.3K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$397,771
765,828 shares
|
— | 26 Jun 2023 |
| BlackRock Finance, Inc. |
13F
Company
|
—
denominator unverified
|
$144,472
15,876 shares
|
— | 31 Dec 2023 |
| NATIXIS |
13F
Company
|
—
denominator unverified
|
$43,278
4,604 shares
|
— | 31 Dec 2023 |
| James Archie Harrell Jr. |
3/4/5
Chief Commercial Officer
|
—
denominator unverified
|
$19,096
36,766 shares
|
— | 10 Dec 2021 |
| H. Jeffrey Wilkins |
3/4/5
Chief Medical Officer
|
—
denominator unverified
|
$17,334
33,373 shares
|
— | 10 Dec 2021 |
| Tower Research Capital LLC (TRC) |
13F
Company
|
—
denominator unverified
|
$16,071
1,766 shares
|
— | 31 Dec 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
18
Shares
87,507
Rows available
18
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2024 vs Q1 2024 Across Filers
Q1 2024 holders
18
Q1 2024 holders
18
Holder diff
0
| Investor | Q1 2024 Shares | Q1 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q1 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend